The discoveries made by scientists across the globe unmasked a number of protein targets and pathways to defeat SARS_CoV_2 which is the causative agent behind COVID19 . Many of these targets have been explored for drug repurposing, but the discovery of a specific drug against a specific target of SARS_CoV_2 is still at large. The main protease (M pro ) of SARS_CoV_2 is one such potential target due to its' essential role in processing the polyproteins that are translated from viral genomic RNA during the viral replication inside the host cell . As the processing of polyproteins is absolutely essential for the replication of the virus, hence it's possible to prevent COVID-19 progression in the host by inhibiting the main protease (M pro ). The solved crystal structure of M pro paved the platform for the computational validation and identification of new leads against the main protease of the virus causing COVID-19 which is still an ongoing global emergency. Importantly, the absence of any human protease with a similar cleaving profile as M Pro rules out the possibility of off-target effects of its inhibitor. Therefore, M Pro is being targeted for drug repurposing and virtual screening in recent times.